Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: Results of a prospective multi-center study

Journal of Neurology

Volumn 257, Issue 2, 2010, Pages 230-237

  Högl, Birgit ^a   García Borreguero, Diego ^b   Kohnen, Ralf ^c,d   Ferini Strambi, Luigi ^e   Hadjigeorgiou, Georgios ^f   Hornyak, Magdolna ^g   De Weerd, Al ^h   Happe, Svenja ^i,j   Stiasny Kolster, Karin ^k   Gschliesser, Viola ^a   Egatz, Renata ^b   Frauscher, Birgit ^a   Benes, Heike ^l,m   Trenkwalder, Claudia ^j,n   Hening, Wayne A ^o   Allen, Richard P ^p  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b SLEEP RESEARCH INSTITUTE   (Spain)

^c Research Pharmaceutical Services (RPS)   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITY OF THESSALY   (Greece)

^g UNIVERSITY OF FREIBURG   (Germany)

^h STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

ⁱ KLINIKUM BREMEN OST   (Germany)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

^l Somni Bene Institute for Medical Research and Sleep Medicine   (Germany)

^m UNIVERSITY OF ROSTOCK   (Germany)

ⁿ Paracelsus Elena Hospital   (Germany)

^o ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Augmentation; Clinical study; Diagnosis; Rating scale; Restless legs syndrome (RLS)

Indexed keywords

BENSERAZIDE; DOMPERIDONE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RESTLESS LEGS SYNDROME; SAMPLE SIZE; TREATMENT DURATION; TREATMENT RESPONSE;

DOPAMINE AGENTS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEVODOPA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77749340689     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5299-8     Document Type: Article

References (26)

1. S Akpinar 1982 Treatment of restless legs syndrome with levodopa plus benserazide Arch Neurol 39 739 1:STN:280:DyaL3s%2FitF2guw%3D%3D 7126008
2. RP Allen CJ Earley 1996 Augmentation of the restless legs syndrome with carbidopa/levodopa Sleep 19 205 213 1:STN:280:DyaK28zgtlymsA%3D%3D 8723377
3. RP Allen D Picchietti WA Hening, et al. 2003 Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health Sleep Med 4 101 119 10.1016/S1389-9457(03)00010-8 14592341 (Pubitemid 36527231)
4. MJ Atkinson A Sinha SL Hass, et al. 2004 Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease Health Qual Life Outcomes 2 12 10.1186/1477-7525-2-12 14987333 (Pubitemid 39112018)
5. MJ Atkinson RP Allen J DuChane, et al. 2004 Validation of the restless legs syndrome quality of life instrument (RLS-QLI): findings of a consortium of national experts and the RLS Foundation Qual Life Res 13 679 693 10.1023/B:QURE.0000021322.22011.d0 1:STN:280:DC%2BD2c3jtV2jsw%3D%3D 15130030 (Pubitemid 38526541)
6. H Benes B Kurella J Kummer J Kazenwadel R Selzer R Kohnen 1999 Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial Sleep 22 1073 1081 1:STN:280: DC%2BD3c%2FotlCmug%3D%3D 10617168
7. H Benes CR Heinrich MA Ueberall R Kohnen 2004 Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial Sleep 27 674 682 15283002
8. C Brodeur J Montplaisir R Godbout R Marinier 1988 Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: a double-blind, controlled study Neurology 38 1845 1848 1:STN:280:DyaL1M%2Flslansw%3D%3D 3057399
9. V Collado-Seidel J Kazenwadel TC Wetter, et al. 1999 A controlled study of additional sr-l-dopa in l-dopa-responsive restless legs syndrome with late-night symptoms Neurology 52 285 290 1:CAS:528:DyaK1MXht1yjtb8%3D 9932945
10. B Frauscher V Gschliesser E Brandauer, et al. 2009 The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels Sleep Med 10 611 615 10.1016/j.sleep.2008.09. 007 19200780
11. D Garcia-Borreguero R Kohnen B Högl, et al. 2007 Validation of the augmentation severity rating scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome Sleep Med 8 455 463 10.1016/j.sleep. 2007.03.023 17543579 (Pubitemid 46972002)
12. D Garcia-Borreguero RP Allen R Kohnen, et al. 2007 Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine - International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute Sleep Med 8 520 530 10.1016/j.sleep.2007.03.022 17544323 (Pubitemid 46972001)
13. D Garcia-Borreguero RP Allen H Benes, et al. 2007 Augmentation as a treatment complication of restless legs syndrome: concept and management Mov Disord 22 Suppl 18 S476 S484 10.1002/mds.21610 17580331
14. PW Kaplan RP Allen DW Buchholz JK Walters 1993 A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene Sleep 16 717 723 1:STN:280: DyaK2c3hvVKhsg%3D%3D 8165385
15. Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C (2004) Severity rating of restless legs syndrome: Validation of the RLS-6 scales. Sleep 27 (Abstract Suppl):A304
16. National Institute of Mental Health (NIMH) (1976) Early clinical drug evaluation unit (ECDEU). Clinical global impressions. In: Guy W (ed) ECDEU assessment manual for psychopharmacology, Revised edn. NIMH, Rockville, pp 218-222
17. W Ondo J Romanyshyn KD Vuong D Lai 2004 Long-term treatment of restless legs syndrome with dopamine agonists Arch Neurol 61 1393 1397 10.1001/archneur.61.9.1393 15364685 (Pubitemid 39202222)
18. WG Ondo 2005 Restless legs syndrome Curr Neurol Neurosci Rep 5 266 274 10.1007/s11910-005-0071-7 15987610
19. K Stiasny-Kolster H Benes I Peglau, et al. 2004 Effective cabergoline treatment in idiopathic restless legs syndrome Neurology 63 2272 2279 1:STN:280:DC%2BD2cnkslWjtQ%3D%3D 15623686
20. C Trenkwalder K Stiasny T Pollmächer, et al. 1995 l-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial Sleep 18 681 688 1:STN:280:DyaK287jtFyhsw%3D%3D 8560135
21. C Trenkwalder V Collado Seidel J Kazenwadel, et al. 2003 One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord 18 1184 1189 10.1002/mds.10503 14534925 (Pubitemid 37336945)
22. C Trenkwalder W Paulus AS Walters 2005 The restless legs syndrome Lancet Neurol 4 465 475 10.1016/S1474-4422(05)70139-3 1:CAS:528:DC%2BD2MXpsFWrt74%3D 16033689 (Pubitemid 40982457)
23. C Trenkwalder H Benes L Grote, et al. 2007 Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial Mov Disord 22 696 703 10.1002/mds.21401 17274039 (Pubitemid 46800141)
24. C Trenkwalder B Högl H Benes R Kohnen 2008 Augmentation in restless legs syndrome is associated with low ferritin Sleep Med 9 572 574 10.1016/j.sleep.2007.07.020 17921065 (Pubitemid 351837476)
25. C von Scheele 1986 Levodopa in restless legs Lancet 2 426 427
26. AS Walters C LeBrocq A Dhar, et al. 2003 Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome Sleep Med 4 121 132 10.1016/S1389-9457(02)00258-7 14592342 (Pubitemid 36527232)